Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% [Yahoo! Finance]
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock [Yahoo! Finance]
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? [Yahoo! Finance]